Introduction Semaglutide, a peptidic GLP-1 receptor agonist, has been clinically approved
for treatment of type 2 diabetes mellitus and is available in subcutaneous and oral dosage …

Background Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease
(NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes …

Aim This systematic review and meta-analysis was conducted to evaluate the efficacy and
safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic
liver disease. The prevalence and disease burden of NAFLD are projected to exponentially …

Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a
conventional anti-obesity drug systematically in obese or overweight patients without …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Obesity is a global health challenge. It is a multifactorial, complex, and progressive disease
associated with various health complications and increased mortality. Lifestyle modifications …

Background. Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients
with type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide 1 receptor agonist, may …

Background The weight loss benefit of semaglutide in patients with diabetes is well-
documented, but its clinical utility in treating obesity among patients without diabetes is less …